A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

When Zepbound, Eli Lilly's highly anticipated weight loss drug, hit the market a year and a half ago, it marked a turning point for the accessibility of weight loss drugs. Since then, Zepbound, the ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

Eli Lilly said it has started selling single-dose vials of its uber-popular weight loss drug Zepbound as demand soars – and the smaller doses cost 50% less than all other obesity medicines.

Eli Lilly weight loss drug Zepbound now available for half its usual price You can now get 2.5-milligram, single-dose vials of Zepbound for $399 per month through Lilly's direct-to-consumer website.

Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 medications have risen in popularity. Investor Alert: Our 10 best stocks ...

Eli Lilly’s weight-loss medicine Zepbound will be available on the website. REUTERS. The website will connect patients to independent telehealth providers who can complement their current team ...

Eli Lilly’s weight loss drug Zepbound generated more than $175 million in just its first few weeks on the market. The company is addressing a market that could reach $100 billion by 2030 ...